Oxbridge Re raises $7.1M via tokenized reinsurance securities

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Oxbridge Re completed five private placements of tokenized reinsurance securities on the Solana blockchain, raising total gross proceeds of approximately $7.1 million. The offerings included three series linked to HCI Group's Fortex Re and two traditional tokenized reinsurance offerings, targeting returns ranging from 17% to 224%. Following the completion, Oxbridge expects to record approximately $13.1 million of new restricted assets on its consolidated balance sheet as collateral.

powered bylight_fuzz_icon
44978344

*this image is generated using AI for illustrative purposes only.

Oxbridge Re has completed five private placements of tokenized reinsurance securities on the Solana blockchain, securing total gross proceeds of approximately $7.1 million from accredited U.S. investors and eligible non-U.S. investors. This capital raise underscores the capability of SurancePlus to originate, structure, and distribute institutional-quality reinsurance investments through blockchain infrastructure. The securities were offered pursuant to Rule 506(c) of Regulation D and Regulation S under the Securities Act of 1933.

The offerings featured three tokenized securities providing synthetic contractual exposure to reinsurance risk associated with HCI Group, Inc.'s Fortex Reinsurance SPC, Ltd. (Fortex Re), alongside the company's traditional tokenized reinsurance offerings. These HCI-related securities were issued as a separate investment structure on blockchain infrastructure and did not affect Fortex Re's or HCI's 2026-2027 reinsurance programs. This structure allows qualified investors to gain blockchain-enabled exposure to specific reinsurance risks without direct participation in the underlying program.

Breakdown of Offerings

The completed offerings consisted of the following series:

Series Type Quantity Issued Price Per Unit Gross Proceeds Target Annual Return Redemption Value
HCI Re 2026 Series A Tokenized Interest 100,000 $11.10 $1.11 million ~224% $36.00
HCI Re 2026 Series B Tokenized Interest 100,000 $22.12 $2.212 million ~122% $49.00
HCI Re 2026 Series C Tokenized Interest 100,000 $30.01 $3.001 million ~17% $35.20
T42-2027 Participation Share 45,335 $10.00 ~$453,357 32% (adjusted) N/A
T20-2027 Participation Share 32,841 $10.00 ~$328,408 26% (adjusted) N/A

The HCI Re 2026 Series A, B, and C target specific annual returns and redemption values assuming no underwriting losses. The T42-2027 and T20-2027 offerings saw adjustments to their originally targeted annual returns, moving to 32% and 26% respectively.

Financial Impact

As a result of the completed offerings, Oxbridge expects to record approximately $13.1 million of new restricted assets on its consolidated balance sheet. These assets represent the collateral supporting the company's tokenized reinsurance securities and participation interests issued through the offerings.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the success of these private placements influence Oxbridge Re's strategy for future tokenized reinsurance offerings on the Solana blockchain?

What impact will the $13.1 million in new restricted assets have on Oxbridge Re's liquidity and ability to pursue additional capital raises?

Could the adjustments to targeted annual returns for the T42-2027 and T20-2027 offerings signal broader market trends for tokenized reinsurance risk pricing?

like15
dislike

Maxim Group maintains Buy on Oxbridge Re, lowers target to $3

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Maxim Group analyst Allen Klee maintains a Buy rating on Oxbridge Re Holdings but lowers the price target from $5 to $3.

powered bylight_fuzz_icon
43268174

*this image is generated using AI for illustrative purposes only.

Maxim Group analyst Allen Klee has maintained a Buy rating on Oxbridge Re Holdings while adjusting the valuation outlook. The price target has been reduced to $3 from the previous $5.

The revised target reflects a reassessment of the company's stock potential despite the continued positive recommendation. The rating indicates that Maxim Group still expects the shares to perform well relative to the broader market.

Metric Value
Rating Buy
New Price Target $3
Previous Price Target $5
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors led to the reassessment of Oxbridge Re Holdings' valuation potential?

How might this price target reduction influence investor sentiment in the short term?

What are the key growth drivers that could help the stock reach the new $3 price target?

like19
dislike

More News on Oxbridge Re Holdings Ltd